These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. Iriuchishima H; Ozaki S; Konishi J; Matsumoto M; Murayama K; Nakamura F; Yamamoto G; Handa H; Saitoh T; Nagura E; Shimizu K; Nojima Y; Murakami H Acta Haematol; 2016; 135(2):113-21. PubMed ID: 26505781 [TBL] [Abstract][Full Text] [Related]
5. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation]. Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483 [No Abstract] [Full Text] [Related]
6. Primary plasma cell leukemia in the era of new drugs: has something changed? Musto P; Pagano L; Petrucci MT; Morabito F; Caravita T; Di Raimondo F; Baldini L; Tosi P; Bringhen S; Offidani M; Omede' P; Neri A; D'Auria F; Bochicchio GB; Cavo M; Boccadoro M; Palumbo A Crit Rev Oncol Hematol; 2012 May; 82(2):141-9. PubMed ID: 21719304 [TBL] [Abstract][Full Text] [Related]
7. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review]. Wang H; Li JY; Sun C; Zhou X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927 [TBL] [Abstract][Full Text] [Related]
8. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Kumar SK; Dimopoulos MA; Kastritis E; Terpos E; Nahi H; Goldschmidt H; Hillengass J; Leleu X; Beksac M; Alsina M; Oriol A; Cavo M; Ocio EM; Mateos MV; O'Donnell EK; Vij R; Lokhorst HM; van de Donk NWCJ; Min C; Mark T; Turesson I; Hansson M; Ludwig H; Jagannath S; Delforge M; Kyriakou C; Hari P; Mellqvist U; Usmani SZ; Dytfeld D; Badros AZ; Moreau P; Kim K; Otero PR; Lee JH; Shustik C; Waller D; Chng WJ; Ozaki S; Lee JJ; de la Rubia J; Eom HS; Rosinol L; Lahuerta JJ; Sureda A; Kim JS; Durie BGM Leukemia; 2017 Nov; 31(11):2443-2448. PubMed ID: 28620163 [TBL] [Abstract][Full Text] [Related]
9. Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. Takamatsu H; Honda S; Miyamoto T; Yokoyama K; Hagiwara S; Ito T; Tomita N; Iida S; Iwasaki T; Sakamaki H; Suzuki R; Sunami K Cancer Sci; 2015 Feb; 106(2):179-85. PubMed ID: 25530023 [TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092 [TBL] [Abstract][Full Text] [Related]
13. [Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents]. Deng JJ; Jin XY; Zhang ZY; Zhou HX; Yang GZ; Geng CY; Jian Y; Chen WM; Gao W Zhonghua Xue Ye Xue Za Zhi; 2024 Jul; 45(7):645-650. PubMed ID: 39231768 [No Abstract] [Full Text] [Related]
14. Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma. Noonan K; Colson K Semin Oncol Nurs; 2017 Aug; 33(3):279-291. PubMed ID: 28666621 [TBL] [Abstract][Full Text] [Related]
15. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Gonsalves WI; Rajkumar SV; Go RS; Dispenzieri A; Gupta V; Singh PP; Buadi FK; Lacy MQ; Kapoor P; Dingli D; Lust JA; Zeldenrust SR; Hayman SR; Kyle RA; Gertz MA; Kumar SK Blood; 2014 Aug; 124(6):907-12. PubMed ID: 24957143 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352 [TBL] [Abstract][Full Text] [Related]
17. Primary plasma cell leukemia 2.0: advances in biology and clinical management. Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436 [TBL] [Abstract][Full Text] [Related]
19. Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group. Peña C; Riva E; Schutz N; Ramírez A; Vásquez J; Del Carpio D; Seehaus C; Ochoa P; Vengoa R; Duarte P; Martínez-Cordero H; Figueredo Y; Ríos RO; Ramírez J; Bove V; Roa M; Russo M; Espinoza M; Rodriguez G; Remaggi G; Enciso ME; Chandía M; Fantl D; Leuk Lymphoma; 2023 Apr; 64(4):816-821. PubMed ID: 36695519 [TBL] [Abstract][Full Text] [Related]
20. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]